Clinical Validation of Unani Pharmacopoeal formulation Majoon Rahul Momineen in Zeeq un Nafas (Bronchial Asthma)
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 240
- 试验地点
- 2
- 主要终点
- Improvement in the sign and symptoms of Zeeq un Nafas (Bronchial Asthma)
研究概览
简要总结
This study is a multicentric open trial in patients with Zeeq un Nafas (Bronchial Asthma) After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria. The patients will be assessed clinically at every week. This includes subjective assessment of general well being and physical examination . The total duration of treatment will be 2 weeks. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy.
Composition of Majoon Rahul Momineen
| S.No. |
Ingredients
Botanical
Quantity
|1
Jauzbuwa
Myristica fragrans Houtt.
45gm
|2
Kateera
Cochlospermum religiosum (Linn.) Alston.
45gm
|3
Irsa
Iris ensata Thunb.
45gm
|4
Barg-e-Gaozaban
Borago officinalis Linn.
5gm
|5
Khusyat-us-Salab
Orchis mascula Linn.
5gm
|6
Tukhm-e-Gazar
Daucus carota Linn.
120gm
|7
Narjeel
Cocos nucifera Linn.
120gm
|8
Darchini
Cinnamomum zeylanicum Blume.
120gm
|9
Habb-e-Sanobar
Pinus gerardiana Wall.
120gm
|10
Shaqaq-ul-Misri
Pastinaca secacul Linn.
210gm,
|11
Sheera-e-Tukhm-e-Khashkhash
Papaver somniferum Linn.
300gm
|12
Joshanda-e-Post-e-Khashkhash
Papaver somniferum Linn.
600gm
|13
Asal or Qand Safaid
Honey or Sugar
5kg
|14
Aab-e-Seb
Malus sylvestris Mill.
1.2ltr
|15
Aab-e-Gazar
Daucus carota Linn.
2ltr
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 19.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Patients of either sex in the age group of 19-60
- •Patients of Bronchial Asthma presenting with the following symptoms: Wheeze Shortness of breath Chest tightness and cough that vary over time and in intensity Expiratory airflow limitation as suggested by a decreased FEV1 Patients with Asthma Control Questionnaire Score < 1.5.
排除标准
- •The patients of Zeequn Nafas (Bronchial Asthma) with following conditions will be excluded from the study:
- •Patient with Upper Respiratory Tract Infections, Chronic obstructive airway disease (COAD) including chronic bronchitis and emphysema.
- •Patient with medical conditions requiring long term treatment such as Pulmonary tuberculosis, Renal insufficiency Diabetes Mellitus, Hypertension etc
- •Patients with cognitive impairments
- •History of addiction (smoking, alcohol, drugs)
- •Pregnant and lactating women.
结局指标
主要结局
Improvement in the sign and symptoms of Zeeq un Nafas (Bronchial Asthma)
时间窗: Two Weeks
次要结局
- Hematological and biochemical assessments for safety(2 weeks)